Dexamethasone study shows promising results for treating COVID-19 patients
The New England Journal of Medicine last week released a study showing that the use of dexamethasone resulted in a lower, 28-day mortality rate among patients receiving invasive ventilation or oxygen.
The study indicated lower incidence of death among 2,104 patients treated with dexamethasone, compared to 4,321 patients receiving usual care. However, results showed very little impact in patients not receiving respiratory support.
The Food and Drug Administration also recently updated its COVID-19 treatment guidelines for corticosteroids, including dexamethasone. FDA said such drugs can be used for up to 10 days in patients requiring supplemental oxygen, but not with those who are mechanically ventilated or do not require supplemental oxygen.
Related News Articles
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…